AOD 9604

AOD 9604 is a synthetic 16-amino-acid peptide (YLRIVQCRSVEGSCGF) based on the C-terminal fragment 177–191 of human growth hormone, with an added N-terminal tyrosine. It was developed in Australia in the late 1990s and 2000s; its clinical development was discontinued and it is not FDA approved.

Peptides can form gels or cloudy, viscous solutions when their chains associate with each other. AOD 9604 contains a disulfide bond and several hydrophobic residues, and gelling becomes more likely at high concentration, at certain pH values, when the solution is cold, or after vigorous shaking. Reconstituting at a lower concentration, adding diluent slowly and swirling rather than shaking all help. Contact us with the lot number if a vial will not dissolve.

Published research on AOD 9604 has examined lipid metabolism pathways in rodent models and in adipose tissue preparations, building on earlier work on the C-terminal region of growth hormone. It was developed in Australia by Metabolic Pharmaceuticals and investigated in clinical trials in people with obesity before development was discontinued in the late 2000s. Findings in cells or animals do not establish effects in people.

No. AOD 9604 has not been approved by the FDA or any other drug regulator, and its clinical development was discontinued. The World Anti-Doping Agency has stated that it falls under its category of non-approved substances, prohibited in sport at all times. It is sold here strictly as a research compound.

Yes. AOD 9604 is a synthetic 16-amino-acid peptide (YLRIVQCRSVEGSCGF) with an internal disulfide bond between its two cysteines. Its sequence is residues 177–191 of human growth hormone with a tyrosine added at the N-terminus. Each lot's identity is confirmed by HPLC and mass spectrometry on the Certificate of Analysis.

No. AOD 9604 is a 16-amino-acid fragment-based peptide, while human growth hormone (HGH 191AA) is a 191-amino-acid protein of about 22 kDa. AOD 9604 reproduces only the last 15 residues of growth hormone plus an added tyrosine, so it lacks most of the hormone's structure. It is a separate research compound, not a form of HGH.

They are closely related and are often sold as the same sequence. In native growth hormone, residues 176–191 read FLRIVQCRSVEGSCGF, beginning with phenylalanine. AOD 9604 is residues 177–191 with a tyrosine added at the N-terminus, YLRIVQCRSVEGSCGF. Many suppliers sell "HGH Fragment 176-191" with that tyrosine version, in which case the two are identical. Check the sequence on each lot's Certificate of Analysis.

No. AOD 9604 is a 16-amino-acid peptide based on the C-terminal end of growth hormone and is not an approved medicine. Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that acts on the GHRH receptor, and it is an FDA-approved active ingredient. They differ in sequence, length and target; both are sold here as research reagents.

For storage, yes. Keep lyophilized AOD 9604 sealed and refrigerated at 2–8 °C, or frozen at −20 °C or below for long-term storage. After reconstitution keep it refrigerated and avoid freeze-thaw cycles; because AOD 9604 solutions can gel when cold and concentrated, a lower concentration and gentle swirling help keep it in solution.

They share a research area but not a structure. Adipotide is a two-part peptidomimetic that targets prohibitin on adipose-tissue blood vessels. AOD 9604 is a 16-amino-acid peptide based on the C-terminal end of human growth hormone (residues 177–191 plus an N-terminal tyrosine). They have no sequence in common and were developed by different groups.

They are very different molecules. HGH 191AA is the full-length 191-amino-acid hormone, made by recombinant expression and folded with two disulfide bridges. HGH fragment 176-191 is a short synthetic peptide matching only the last 16 residues of the hormone's C-terminus; AOD 9604 is a closely related synthetic peptide of the same length. A 16-residue fragment does not have the folded structure of the full hormone.

AOD 9604: molecular formula C78H123N23O23S2; molecular weight 1815.1 g/mol; CAS number 221231-10-3. Sequence: YLRIVQCRSVEGSCGF. Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 5mg (99.74% HPLC purity); 10mg (98.61% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

98.61% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

AOD 9604 is supplied as lyophilized powder in a sealed vial in 2 sizes: 5mg, 10mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.